Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.

about

Neutrophils in animal models of autoimmune disease

P2860

Q36902110-4ACACF47-819B-4D47-9515-FFC83B83617E

P2860

Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.

Item

http://www.wikidata.org/entity/Q38747383

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.

@en

type

Item

label

Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.

@en

prefLabel

Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.

@en

P1476

Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.

@en

P2093

Huza Zhang

http://www.w3.org/2001/XMLSchema#string

Maria J Cuadrado

http://www.w3.org/2001/XMLSchema#string

Savino Sciascia

http://www.w3.org/2001/XMLSchema#string

William Chambers

http://www.w3.org/2001/XMLSchema#string

P2860

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

Rationale for interleukin-6 blockade in systemic lupus erythematosus

The human U1-70K snRNP protein: cDNA cloning, chromosomal localization, expression, alternative splicing and RNA-binding

Pathogenesis of systemic lupus erythematosus

B-cell survival factors in autoimmune rheumatic disorders

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Autophagy in infection, inflammation, and immunity

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

P304

681-694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2016.1155446

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26907827

http://www.w3.org/2001/XMLSchema#string

Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.

about

P2860

P2860

Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698